TMS Co Ltd Sustainability Reports
TMS Co., Ltd. operates as a clinical-stage biotechnology enterprise engaged in the research and development of pharmaceutical products and medical devices. The company focuses primarily on the development of therapeutic compounds derived from Stachybotrys microspora triprenyl phenol (SMTPs) for the treatment of acute ischemic stroke and other indications.
Sector: Manufacturing
Country: Japan
Exchange: Tokyo Stock Exchange
FIGI: BBG001TWZQ09
3 reports from 2023 to 2025